We retrospectively characterized fusion variant distribution in a cohort of ALK+ lung adenocarcinomas (ADC) with paired clinical data about treatments and outcomes.Diagnostic tumor tissue from advanced ALK+ (by FISH and/or IHC) ADC diagnosed from 2010 to 2018 and treated with single or multiple ALKis were collected (expanded cohort from Gobbini et al. Lung Cancer, 2017). The OncomineTM Solid Tumor Fusion Transcript Kit on an Ion PGM™ system and the Ion Reporter™ software were used to identify targeted ALK fusion gene products (ThermoFisher).Our analysis suggests that different ALK fusion variant might affect ALKi treatment duration in ALK+ lung ADC READ ARTICLE
Journal of Thoracic Oncology DOI:10.1016/j.jtho.2019.08.1177
Authors: F. Tabbò, E. Gobbini, L. Muscarella, A. Rigutto, D. Trombetta, A. Bonfitto, D. Galetta, E. Maiello, O. Martelli, M. Tiseo, P. Bordi, V. Scotti, L. Ghilardi, V. Gregorc, C. Sergi, S. Pilotto, A. Del, Conte, F. Cappuzzo, D. Cortinovis, G. Osman, C. Bareggi, M. Di Maio, A. Rossi, G. Rossi, E. Bria, M. Volante, G. Scagliotti, P. Graziano, S. Novello, L. Righi
